- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00636961
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)
July 29, 2011 updated by: Novartis
An Exploratory, Double Blind, Randomized, Placebo-controlled, 2-way Cross-over Study to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With COPD
This study evaluated the effect of QAB149 on dynamic and static hyperinflation, breathlessness, and health status in COPD patients
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany
- Novartis Investigator Site
-
Mönchengladbach, Germany
- Novartis Investigator Site
-
Wiesbaden, Germany
- Novartis Investigator Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects,
- 40 to 80 years of age,
- with a documented diagnosis of mild, moderate or severe chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and >20-pack year history of smoking, a post-bronchodilator 40% ≤ FEV1 ≤ 80% of predicted normal and post-bronchodilator FEV1/FVC < 70% who have signed an informed consent form (ICF) prior to the initiation of any study-related procedure (Post bronchodilator refers to 30 minutes after the inhalation of 400 µg of salbutamol)
- Subjects who demonstrate a plethysmographic functional residual capacity >120% predicted normal
Exclusion Criteria:
- No COPD exacerbations within 6 weeks prior to dosing,
- no concomitant lung disease such as asthma,
- no requirement for long term oxygen treatment or history of lung reduction surgery.
- No medical conditions that would interfere with the performance of spirometry or clinical exercise testing.
- Any other medical condition that in the opinion of the investigator may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from participating in the study e.g. uncontrolled hypertension or unstable ischemic heart disease
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence 1: Indacaterol 300μg followed by Placebo
In period I, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks.
In period II, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks.
For each treatment period and for each patient, the doses were to be administered between 7am and 12am.
A period of at least 4 days but no more than 21 days separated each treatment period.
Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
|
300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
Other Names:
Matching placebo devices and hard gelatin capsules
|
Experimental: Sequence 2 : Placebo followed by Indacaterol 300μg
In period I, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks.
In period II, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks.
For each treatment period and for each patient, the doses were to be administered between 7am and 12am.
A period of at least 4 days but no more than 21 days separated each treatment period.
Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
|
300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
Other Names:
Matching placebo devices and hard gelatin capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inspiratory Capacity (IC) at Peak Time and at Isotime on Day 14
Time Frame: Day 14
|
Inspiratory capacity (IC) at peak time and at isotime were the primary pharmacodynamic (PD) variables of interest.
IC was measured at two minute intervals during exercise.
Isotime was defined as the time the subject was still exercising in the shortest of all sub-maximal exercise tests (3-minutes resting pedaling, 3-minutes unloaded pedaling and exercise with loaded pedaling).
Peak time was defined as the last measurement taken in the exercise period.
The primary analysis consisted of a linear mixed effects model with baseline IC measurement as covariate.
|
Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Static Inspiratory Capacity (IC) at Day 14
Time Frame: Day 14
|
Inspiratory Capacity (IC) at resting (static IC) was measured by using whole body plethysmography.
The day 14 measurement was analyzed using an analysis of variance including baseline (day -2) as a covariate,
|
Day 14
|
Trough Forced Expiratory Volume in 1 Second (FEV1) Measured by Spirometry on Day 14
Time Frame: Day 14
|
FEV1 was measured with spirometry conducted according to internationally accepted standards.
Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose.
The linear mixed model included the baseline FEV1 measurement as covariate.
|
Day 14
|
Chronic Activity Related Breathlessness Measured by Transition Dyspnoea Index (TDI) at Day 14
Time Frame: Day 14
|
Dyspnoea was measured during the treatment period using the transition dyspnoea index (TDI), which captures changes from baseline.
The TDI has three domains; functional impairment, magnitude of task and magnitude of effort.
TDI domains are rated from -3 (major deterioration) to 3 (major improvement) and rates are summed for transition focal score ranging from -9 to 9; minus scores indicate deterioration.
A TDI focal score of 1 was considered to be a clinically significant and meaningful improvement from baseline.
Analysis of variance included period baseline dyspnoea index (BDI) as covariate.
|
Day 14
|
Dyspnoea Measured by Borg CR10 Scale at Day 1, Day 14
Time Frame: Day 1, Day 14
|
The modified Borg CR10 Scale consists of 12-point score that the patients point to so as to indicate their level of dyspnoea (where 0 indicates no breathlessness at all to 12 indicates maximum breathlessness), before and during exercise testing.
A reduction in this score indicates an improvement.
Isotime was defined as the time the subject was still exercising in the shortest of all sub-maximal exercise tests.
Peak time was defined as the last measurement taken in the exercise period.
Analysis of variance included period, treatment and sequence as fixed effects and subject as random effect.
|
Day 1, Day 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2008
Primary Completion (Actual)
August 1, 2008
Study Completion (Actual)
August 1, 2008
Study Registration Dates
First Submitted
March 10, 2008
First Submitted That Met QC Criteria
March 10, 2008
First Posted (Estimate)
March 17, 2008
Study Record Updates
Last Update Posted (Estimate)
August 30, 2011
Last Update Submitted That Met QC Criteria
July 29, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CQAB149B2318
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Indacaterol 300μg
-
Novartis PharmaceuticalsCompleted
-
Yuan-Ming LuoCompletedChronic Obstructive Pulmonary DiseaseChina
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)France
-
Novartis PharmaceuticalsCompletedAsthmaSouth Africa, Belgium, Croatia, Turkey, Hungary, Colombia, Slovakia, Philippines, Russian Federation, Guatemala, Germany
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)China, Australia, India
-
Morten Hostrup, PhDRecruiting
-
Novartis PharmaceuticalsCompletedAsthmaGermany, United Kingdom
-
Novartis PharmaceuticalsCompletedPatients With Moderate-to-severe COPD With Destroyed Lung by TuberculosisKorea, Republic of
-
NovartisCompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Novartis PharmaceuticalsCompletedPersistent AsthmaUnited States, Netherlands, United Kingdom, France, Germany, Jordan